{
    "clinical_study": {
        "@rank": "48585", 
        "arm_group": [
            {
                "arm_group_label": "REGN2009 dose level 1", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)"
            }, 
            {
                "arm_group_label": "REGN2009 dose level 2", 
                "arm_group_type": "Experimental", 
                "description": "Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)"
            }, 
            {
                "arm_group_label": "REGN2009 dose level 3", 
                "arm_group_type": "Experimental", 
                "description": "Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled first-in-human (FIH) study\n      to assess the safety and tolerability of ascending single doses of REGN2009 administered to\n      healthy volunteers."
        }, 
        "brief_title": "Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy men and women ages 18 to 65 years inclusive\n\n          2. Body mass index between 18.0 kg/m^2 and 30.0 kg/m^2, inclusive\n\n        Exclusion Criteria:\n\n          1. Pregnant or breast-feeding women\n\n          2. Any clinically significant abnormalities observed during screening (day -21 to day\n             -2)\n\n          3. Known history of human immunodeficiency virus (HIV) antibody; and/or positive\n             hepatitis B surface antigen, and/or positive hepatitis C antibody at the screening\n             visit\n\n          4. History of drug or alcohol abuse within a year prior to the screening visit (day -21\n             to day -2)\n\n          5. Hospitalization for any reason within 60 days of the screening visit (day -21 to day\n             -2)\n\n          6. Participation in any clinical research study within 30 days of the screening visit\n             (day -21 to day -2) or within 5 half-lives of the investigational drug or therapy\n             being studied (whichever is longer)\n\n          7. History of a hypersensitivity reaction to doxycycline or similar compound\n\n          8. Any medical or psychiatric condition which, in the opinion of the investigator, would\n             place the subject at risk, interfere with participation in the study or interfere\n             with the interpretation of the study results\n\n          9. Previous adverse experience to any biological investigational or therapeutic agent\n\n         10. Sexually active men or women of childbearing potential who are unwilling to practice\n             adequate contraception during the study\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial and not all inclusion/ exclusion\n        criteria are listed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893528", 
            "org_study_id": "R2009-HV-1304"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "REGN2009 dose level 1", 
                    "REGN2009 dose level 2", 
                    "REGN2009 dose level 3"
                ], 
                "intervention_name": "REGN2009", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "REGN2009 dose level 1", 
                    "REGN2009 dose level 2", 
                    "REGN2009 dose level 3"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint in this study is the incidence and severity of Treatment Emergent Adverse Events (TEAEs) in healthy volunteers treated with REGN2009 or placebo reported from day 1 (baseline) to the completion of the study on day 106/ visit 15.", 
            "measure": "Number of TEAEs", 
            "safety_issue": "Yes", 
            "time_frame": "day 1 to day 106/ visit 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893528"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}